January 5, 2005Confidentiality Agreement • January 11th, 2005 • Lam Pharmaceutical Corp • Pharmaceutical preparations • New York
The purpose of this provisional sale and purchase letter agreement (the “Provisional Agreement”) is to outline the terms of a proposed acquisition (the “Proposed Acquisition”) by LAM Pharmaceutical Corporation (the “Acquiror”) of 51% of the outstanding shares of Hynature Investments Ltd. (“Hynature”), all of which are owned by Finest Enterprises Limited (“Seller”), on the terms and subject to the conditions to be set forth in a definitive stock purchase agreement to be executed by the parties. The proposed terms of the acquisition are as follows.
